Should I buy or sell Jazz Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks .

What is Jazz Pharmaceuticals' stock price target for 2024?

13 analysts have issued 12 month target prices for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $131.00 to $230.00. On average, they expect the company's share price to reach $195.08 in the next year. This suggests a possible upside of 76.8% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts .

How have JAZZ shares performed in 2024?

Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ shares have decreased by 10.3% and is now trading at $110.32. View the best growth stocks for 2024 here .

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our JAZZ earnings forecast .

How can I listen to Jazz Pharmaceuticals' earnings call?

Jazz Pharmaceuticals will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by $0.04. The specialty pharmaceutical company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 31.27% and a net margin of 10.82%.

What ETFs hold Jazz Pharmaceuticals' stock?

ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE) , SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , VanEck Pharmaceutical ETF (PPH) , Invesco Pharmaceuticals ETF (PJP) , iShares U.S. Pharmaceuticals ETF (IHE) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) and AdvisorShares Pure Cannabis ETF (YOLO) .

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus EPS estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com . Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Micron Technology (MU) , NVIDIA (NVDA) , Netflix (NFLX) , Tesla (TSLA) , AbbVie (ABBV) , Bank of America (BAC) and Biogen (biib) .

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Perpetual Ltd (0.75%), Los Angeles Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Centre Asset Management LLC (0.11%), Graphene Investments SAS (0.04%) and Hennion & Walsh Asset Management Inc. (0.04%). Insiders that own company stock include Anne Oriordan , Bruce C Cozadd, Bruce C Cozadd , Christopher J Tovey , Elmar Schnee , Finbar Larkin , James E Flynn, Jennifer E Cook , Kenneth W O'keefe , Kim Sablich , Mark Douglas Smith , Neena M Patil , Patricia Carr , Patrick G Enright , Peter Gray , Philip L Johnson, Renee D Gala , Rick E Winningham , Robert Iannone and Samantha Pearce . View institutional ownership trends .

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion. Read More

Top-Rated StocksTop-Rated

NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free JAZZ Stock Alerts

$110.32

+1.05 (+0.96%)

(As of 03:27 PM ET)

Compare

Today's Range: $108.88
▼
$111.35
50-Day Range: $107.10
▼
$132.77
52-Week Range: $106.61
▼
$146.70

Volume: 396,029 shs
Average Volume: 609,934 shs
Market Capitalization: $6.95 billion

P/E Ratio: 18.03
Dividend Yield: N/A
Price Target: $195.08

Get Jazz Pharmaceuticals alerts:

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 76.8% Upside
$195.08 Price Target
Short Interest: Bearish
5.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.72
Based on 10 Articles This Week
Insider Trading: Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth: 14.72%
From $16.24 to $18.63 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.84 out of 5 stars

Medical Sector

43rd out of 918 stocks

Pharmaceutical Preparations Industry

13th out of 417 stocks

4.4

Analyst's Opinion

Consensus Rating
Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Jazz Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.41% of the float of Jazz Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Jazz Pharmaceuticals has recently increased by 17.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Jazz Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Jazz Pharmaceuticals does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Jazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.
Environmental Sustainability
The Environmental Impact score for Jazz Pharmaceuticals is -1.96.

2.6

News and Social Media Coverage

News Sentiment
Jazz Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.
Search Interest
Only 6 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jazz Pharmaceuticals insiders have bought 519.89% more of their company's stock than they have sold. Specifically, they have bought $1,435,800.00 in company stock and sold $231,623.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.
Percentage Held by Institutions
89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Jazz Pharmaceuticals are expected to grow by 14.72% in the coming year, from $16.24 to $18.63 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Jazz Pharmaceuticals is 18.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of Jazz Pharmaceuticals is 18.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.50.
Price to Earnings Growth Ratio
Jazz Pharmaceuticals has a PEG Ratio of 1.48. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Jazz Pharmaceuticals has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

JAZZ Stock News Headlines

April 18, 2024 | seekingalpha.com

Jazz Pharmaceuticals: Cheap But Complicated

April 17, 2024 | prnewswire.com

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 14, 2024 | americanbankingnews.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 12-Month Low at $111.11

April 13, 2024 | msn.com

Cannabis compound d-limonene reduces anxiety-inducing effects of THC

April 11, 2024 | americanbankingnews.com

Cantor Fitzgerald Reiterates Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

April 10, 2024 | markets.businessinsider.com

Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views

April 10, 2024 | prnewswire.com

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 2, 2024 | finance.yahoo.com

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

April 1, 2024 | msn.com

10 songs for the total solar eclipse with the word ‘eclipse’ in the lyrics

March 28, 2024 | finanznachrichten.de

Jazz Pharmaceuticals: Cancer and the Combination Approach

March 28, 2024 | finance.yahoo.com

Cancer and the Combination Approach

March 21, 2024 | msn.com

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

March 21, 2024 | markets.businessinsider.com

Optimistic Outlook on Jazz Pharmaceuticals’ Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis

March 20, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Jazz Pharmaceuticals on Strong Zanidatamab Revenue Prospects and Clinical Milestones

March 20, 2024 | markets.businessinsider.com

The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals

March 20, 2024 | finance.yahoo.com

Jazz Pharmaceuticals Celebrates International Women’s Day

March 16, 2024 | finance.yahoo.com

JAZZ Apr 2024 110.000 put

March 14, 2024 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know

March 14, 2024 | finance.yahoo.com

Unlocking Jazz Pharmaceuticals' Potential: A Roadmap for Growth

March 14, 2024 | finance.yahoo.com

Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month

March 13, 2024 | investorplace.com

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

March 12, 2024 | msn.com

Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users

March 12, 2024 | prnewswire.com

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

March 12, 2024 | finance.yahoo.com

Jazz Pharmaceuticals (NASDAQ:JAZZ) shareholders have endured a 32% loss from investing in the stock three years ago

March 12, 2024 | markets.businessinsider.com

Strong Buy Rating for AnaptysBio Based on Promising Pipeline and Financial Health

See More Headlines

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:JAZZ
CUSIP: G5087110
CIK: 1232524
Web: www.jazzpharma.com
Phone: (531) 634-7800
Fax: 353-1634-7850
Employees: 2,800
Year Founded: 2003

Price Target and Rating

Average Stock Price Target: $195.08
High Stock Price Target: $230.00
Low Stock Price Target: $131.00
Potential Upside/Downside: +78.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.12
Trailing P/E Ratio: 17.82
Forward P/E Ratio: 6.72
P/E Growth: 1.48
Net Income: $414.83 million
Net Margins: 10.82%
Pretax Margin: 7.77%
Return on Equity: 31.27%
Return on Assets: 9.81%

Debt

Debt-to-Equity Ratio: 1.37
Current Ratio: 2.24
Quick Ratio: 1.85

Sales & Book Value

Annual Sales: $3.83 billion
Price / Sales: 1.79
Cash Flow: $28.33 per share
Price / Cash Flow: 3.85
Book Value: $59.36 per share
Price / Book: 1.84

Miscellaneous

Outstanding Shares: 63,000,000
Free Float: 60,228,000
Market Cap: $6.87 billion
Optionable: Optionable
Beta: 0.59

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Bruce C. Cozadd (Age 60)
Co-Founder, Chairman & CEO
Comp: $2.45M
Ms. Reneé D. Galá (Age 52)
President & COO
Comp: $1.13M
Dr. Robert Iannone M.D. (Age 57)
Executive VP and Global Head of Research & Development
Comp: $1.08M
Mr. Philip L. Johnson
Executive VP & CFO
Ms. Patricia Carr (Age 52)
Senior VP & Chief Accounting Officer
Ms. Andrea N. Flynn Ph.D.
VP & Head of Investor Relations
Ms. Neena M. Patil J.D. (Age 48)
Executive VP & Chief Legal Officer
Comp: $331.61k
Ms. Heidi Manna (Age 52)
Executive VP & Chief People Officer
Dr. Jed Black M.D.
Senior Vice President of Sleep & CNS Medicine
Ms. Samantha Pearce (Age 58)
Senior Vice President of Europe & International

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings or view top-rated stocks.
What is Jazz Pharmaceuticals' stock price target for 2024?: 13 analysts have issued 12 month target prices for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $131.00 to $230.00. On average, they expect the company's share price to reach $195.08 in the next year. This suggests a possible upside of 76.8% from the stock's current price.
View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts.
How have JAZZ shares performed in 2024?: Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ shares have decreased by 10.3% and is now trading at $110.32.
View the best growth stocks for 2024 here.
When is Jazz Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our JAZZ earnings forecast.
How can I listen to Jazz Pharmaceuticals' earnings call?: Jazz Pharmaceuticals will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Jazz Pharmaceuticals' earnings last quarter?: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by $0.04. The specialty pharmaceutical company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 31.27% and a net margin of 10.82%.
What ETFs hold Jazz Pharmaceuticals' stock?: ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include Cambria Cannabis ETF (TOKE), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), VanEck Pharmaceutical ETF (PPH), Invesco Pharmaceuticals ETF (PJP), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Nasdaq Pharmaceuticals ETF (FTXH) and AdvisorShares Pure Cannabis ETF (YOLO).

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?: Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus EPS estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.
What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?: 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Jazz Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).
Who are Jazz Pharmaceuticals' major shareholders?: Jazz Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Perpetual Ltd (0.75%), Los Angeles Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Centre Asset Management LLC (0.11%), Graphene Investments SAS (0.04%) and Hennion & Walsh Asset Management Inc. (0.04%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends.
How do I buy shares of Jazz Pharmaceuticals?: Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Jazz Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More

This page (NASDAQ:JAZZ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

JAZZ Stock Price History

JAZZ Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

JAZZ Stock Analysis - Frequently Asked Questions

Overall MarketRank^™